Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2018

View Archived Issues

Gene therapy for dominant blindness

Wee1 is a target in rhabdomyosarcoma

KW-6356 affects motor scores in phase II early Parkinson's disease trial

Liver-targeted prodrug may prove effective in fibrosis

DA-9701 may improve gastric motility in Parkinson's disease patients

Amgen targets the apelin receptor with AMG-986 for heart failure therapy

Lenvima approved in Europe as first-line treatment in adults with advanced or unresectable HCC

Toca 5 pivotal phase III study of Toca-511/Toca-FC continues without modification

Preclinical data and structure described for next-generation TYK2 inhibitor PF-06826647

GlaxoSmithKline presents leucine-rich repeat serine/threonine-protein kinase 2 inhibitors

Yangzhou Blue Biomedical Technology Co. patents penicilone derivatives

N-acetyl-beta-D-glucosaminidase inhibitors identified at Janssen

University of South Australia discloses cyclin-dependent kinase inhibitors

New selective Mcl-1 inhibitors with in vivo activity described by Vanderbilt University

DSMB completes new review of safety data from FOCUS trial of melphalan/HDS

FDA approves Takhzyro for prevention of HAE attacks

FDA approves Diacomit for seizures associated with Dravet syndrome

Telix submits CTA to begin phase III trial in Europe with TLX-250 for renal cancer imaging

FDA approves Inveltys for post-operative inflammation and pain

bluebird bio and Gritstone Oncology establish cancer cell therapy collaboration

FDA approves cobas EGFR Mutation Test v2 as companion diagnostic test with Iressa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...